Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

When to tissue type siblings in poor responders

  • Ruth Spearing
  • Ruth Spearing's Avatar Topic Author
1 year 1 month ago #1629 by Ruth Spearing
A female patient aged 35 who 7 years after diagnosis still has a BCR-ABL of 0.011 . Slipped up to 0.033 but came back down again without changing anything. Her facial oedema on the 200mg bd of imatinib isn’t too bad with H1 and H2 blockers, but she had quite a marked facial burning with nilotinib (although I didn’t try H1 and H2 blockers at that stage) and small pleural and abdominal effusions with dasatinib, along with a change of taste.
Would there be an indication to have at least tissue type her siblings or am I worrying unnecessarily?
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
1 year 1 month ago #1630 by Tim Hughes
Replied by Tim Hughes on topic When to tissue type siblings in poor responders
Looking at her PCR chart, her BCR-ABL values haven’t really fallen over the past 2 years. This means it is unlikely she will be a candidate for an attempt at TFR any time soon on her current therapy. That is not too unusual since she is only 7 years from diagnosis. This might be a problem if she is very keen to get off her TKI therapy soon. In that case it might be justified to retry nilotinib under H1 and H2 blockade if she is willing.
If she is not highly motivated to pursue TFR then you don’t really have a problem, unless she loses MMR. The risk of disease progression is extremely low, as long as she stays on a TKI.
Regarding the need to get prepared for an allograft just in case - I wouldn’t do that unless she lost MMR, because the chances of needing to go to an allograft are still less than 5%


ORIGINAL CASE:
A female patient aged 35 who 7 years after diagnosis still has a BCR-ABL of 0.011 . Slipped up to 0.033 but came back down again without changing anything. Her facial oedema on the 200mg bd of imatinib isn’t too bad with H1 and H2 blockers, but she had quite a marked facial burning with nilotinib (although I didn’t try H1 and H2 blockers at that stage) and small pleural and abdominal effusions with dasatinib, along with a change of taste.
Would there be an indication to have at least tissue type her siblings or am I worrying unnecessarily?
  • jeff lipton
  • jeff lipton's Avatar Topic Author
1 year 1 month ago - 1 year 1 month ago #1631 by jeff lipton
Replied by jeff lipton on topic When to tissue type siblings in poor responders
I tend to be a little put off by the topic "poor responders". Tim alludes to this and I could not agree more with him. Transplant is not in the cards for this patient. They have a good response, albeit not good enough to consider TFR, and remaining on TKI will likely keep them out of any trouble. They do have side effects from the treatment however and I am not sure that any drug switch will necessarily help here.
Although TFR is a goal we would all like to see, it will not be a reality for the majority of patients. For the majority of these individuals, survival equivalent to age matched controls while on therapy is attainable and considering this to be a failure is minimizing the efficacy of the therapy.

ORIGINAL CASE:
A female patient aged 35 who 7 years after diagnosis still has a BCR-ABL of 0.011 . Slipped up to 0.033 but came back down again without changing anything. Her facial oedema on the 200mg bd of imatinib isn’t too bad with H1 and H2 blockers, but she had quite a marked facial burning with nilotinib (although I didn’t try H1 and H2 blockers at that stage) and small pleural and abdominal effusions with dasatinib, along with a change of taste.
Would there be an indication to have at least tissue type her siblings or am I worrying unnecessarily?
Last edit: 1 year 1 month ago by Nicola.
Moderators: Melissa Davis-Bishop